Diligence memo · auto-generated · as of July 2, 2026

Apollo Neuroscience, Inc.

Apollo Neuroscience, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

SourceModeled below same-niche peers while still financing on rhythm — a potential mispricing worth a closer look.

Businessfiled

Apollo Neuroscience, Inc. operates in Other Health Care, based in PITTSBURGH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Apollo Neuroscience, Inc. has raised $24M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $9.3M on 2023-02-09.

Most recent recorded round closed around 2024-04-15.

Valuation (modeled)modeled

Provath models Apollo Neuroscience, Inc. at approximately $2.6M (range $641K–$5.9M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.07× the median modeled value of Series A Other Health Care companies in 2022–2024 (196 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 8 months.

Last raise 2.2 yr ago; this sector typically re-raises about every 14 months.

Slightly overdue versus sector cadence.

The last round was 12.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 86% of Other Health Care peers (5377 compared).

Modeled value ranks above 11% of those peers.

Closest niche peers: CareHarmony, Inc., Dragonfly Endoscopy Inc., NuvoAir Holdings, Inc., Post Acute Recovery, Inc., Micro Interventional Devices, Inc..

Peoplefiled

5 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.